Literature DB >> 9864231

Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease.

C R Marinho1, M R D'Império Lima, M G Grisotto, J M Alvarez.   

Abstract

To obtain low and high parasite loads in the acute phase of Chagas' disease, A/J mice were infected with 10(3) or 10(5) Trypanosoma cruzi trypomastigotes of the Y strain and treated on day 6 with benznidazol. One year later, chronically infected mice were screened for subpatent parasitemias, tissue pathology, and immune response. Mice infected with the high parasite inoculum showed higher levels of chronic parasitemias, heart and striated muscle inflammation, and activation of the immune system than did mice infected with the low inoculum. Concerning the activation of the immune system, the main findings for high-dose-infected mice were (i) increased numbers of splenocytes, with preferential expansion of CD8(+) and B220(-) CD5(-) cells, many of them bearing a macrophage phenotype; (ii) higher frequencies of B (B220(+)), CD4(+), and CD8(+) large lymphocytes; (iii) a shift of CD4(+) cells towards a CD45RBLow phenotype; (iv) increased frequencies of both CD45RBLow and CD45RBHigh large CD4(+) cells; (v) augmented numbers of total immunoglobulin (Ig)-secreting cells, with predominance of IgG2a-producing cells; and (vi) increased production of gamma interferon and interleukin 4. In addition, these mice presented lower IgM and higher IgG2a and IgG1 parasite-specific serum antibody levels. Our results indicate that the parasite load at the acute phase of T. cruzi infection influences the activation of the immune system and development of Chagas' disease pathology at the late chronic phase of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9864231      PMCID: PMC96312     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection.

Authors:  I A Abrahamsohn; R L Coffman
Journal:  Exp Parasitol       Date:  1996-11       Impact factor: 2.011

2.  "Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue.

Authors:  R L Tarleton; L Zhang; M O Downs
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells.

Authors:  J D Sedgwick; P G Holt
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

4.  Studies of Trypanosoma cruzi clones in inbred mice. III. Histopathological and electrocardiographical responses to chronic infection.

Authors:  M Postan; J J Bailey; J A Dvorak; J P McDaniel; E W Pottala
Journal:  Am J Trop Med Hyg       Date:  1987-11       Impact factor: 2.345

5.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

6.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.

Authors:  R Viotti; C Vigliano; H Armenti; E Segura
Journal:  Am Heart J       Date:  1994-01       Impact factor: 4.749

7.  Characterization of cytokine production in murine Trypanosoma cruzi infection by in situ immunocytochemistry: lack of association between susceptibility and type 2 cytokine production.

Authors:  L Zhang; R L Tarleton
Journal:  Eur J Immunol       Date:  1996-01       Impact factor: 5.532

8.  Modification of T-cell proliferation and interleukin 2 production in mice infected with Trypanosoma cruzi.

Authors:  A Harel-Bellan; M Joskowicz; D Fradelizi; H Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

9.  Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment.

Authors:  M A Segura; E Molina de Raspi; M A Basombrio
Journal:  Mem Inst Oswaldo Cruz       Date:  1994 Apr-Jun       Impact factor: 2.743

10.  Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity.

Authors:  F Powrie; R Correa-Oliveira; S Mauze; R L Coffman
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  31 in total

1.  Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection.

Authors:  V Michailowsky; N M Silva; C D Rocha; L Q Vieira; J Lannes-Vieira; R T Gazzinelli
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 2.  Cardiac involvement with parasitic infections.

Authors:  Alicia Hidron; Nicholas Vogenthaler; José I Santos-Preciado; Alfonso J Rodriguez-Morales; Carlos Franco-Paredes; Anis Rassi
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas' disease morbidity?

Authors:  D M Vitelli-Avelar; R Sathler-Avelar; R L Massara; J D Borges; P S Lage; M Lana; A Teixeira-Carvalho; J C P Dias; S M Elói-Santos; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  Influence of Trypanosoma cruzi chronic infection in the depletion of esophageal neurons in Calomys callosus.

Authors:  Leony Cristina Caetano; Sérgio Zucoloto; Laura Midori Kawasse; Miriam Paula Alonso Toldo; José Clóvis Júnior do Prado
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

5.  During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment.

Authors:  Malcolm S Duthie; Stuart J Kahn
Journal:  Immunology       Date:  2006-07-26       Impact factor: 7.397

6.  Blood Gene Signatures of Chagas Cardiomyopathy With or Without Ventricular Dysfunction.

Authors:  Ludmila Rodrigues Pinto Ferreira; Frederico Moraes Ferreira; Helder Imoto Nakaya; Xutao Deng; Darlan da Silva Cândido; Lea Campos de Oliveira; Jean-Noel Billaud; Marion C Lanteri; Vagner Oliveira-Carvalho Rigaud; Mark Seielstad; Jorge Kalil; Fabio Fernandes; Antonio Luiz P Ribeiro; Ester Cerdeira Sabino; Edecio Cunha-Neto
Journal:  J Infect Dis       Date:  2017-02-01       Impact factor: 5.226

Review 7.  Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.

Authors:  Juan Carlos Villar; Juan Guillermo Perez; Olga Lucia Cortes; Adelina Riarte; Micah Pepper; Jose Antonio Marin-Neto; Gordon H Guyatt
Journal:  Cochrane Database Syst Rev       Date:  2014-05-27

8.  Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection.

Authors:  Mustapha Chamekh; Vincent Vercruysse; Mohammed Habib; Maxime Lorent; Michel Goldman; Abdelmounaïm Allaoui; Bernard Vray
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

9.  Challenge of chronically infected mice with homologous trypanosoma cruzi parasites enhances the immune response but does not modify cardiopathy: implications for the design of a therapeutic vaccine.

Authors:  Christian Emerson Rosas-Jorquera; Luiz Roberto Sardinha; Fernando Delgado Pretel; André Luis Bombeiro; Maria Regina D'Império Lima; José Maria Alvarez
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

10.  The liver plays a major role in clearance and destruction of blood trypomastigotes in Trypanosoma cruzi chronically infected mice.

Authors:  Luiz Roberto Sardinha; Tainá Mosca; Rosa Maria Elias; Rogério Silva do Nascimento; Lígia A Gonçalves; Daniella Zanetti Bucci; Cláudio Romero Farias Marinho; Carlos Penha-Gonçalves; Maria Regina D'Império Lima; José Maria Alvarez
Journal:  PLoS Negl Trop Dis       Date:  2010-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.